John M. Evans - Oct 6, 2021 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role
CEO, Director
Signature
By: /s/ Christine Bellon, Attorney-in-fact
Stock symbol
BEAM
Transactions as of
Oct 6, 2021
Transactions value $
-$3,968,737
Form type
4
Date filed
10/8/2021, 04:21 PM
Previous filing
Aug 20, 2021
Next filing
Feb 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BEAM Common Stock Options Exercise $28.5K +27.7K +2.68% $1.03* 1.06M Oct 6, 2021 Direct F1
transaction BEAM Common Stock Sale -$260K -3.15K -0.3% $82.72 1.06M Oct 6, 2021 Direct F2, F3
transaction BEAM Common Stock Sale -$1.12M -13.4K -1.27% $83.47 1.04M Oct 6, 2021 Direct F2, F4
transaction BEAM Common Stock Sale -$882K -10.4K -1% $84.45 1.03M Oct 6, 2021 Direct F2, F5
transaction BEAM Common Stock Sale -$59.7K -701 -0.07% $85.19 1.03M Oct 6, 2021 Direct F2, F6
transaction BEAM Common Stock Sale -$180K -2.17K -1.07% $82.71 201K Oct 6, 2021 By John M. Evans, III 2018 Irrevocable Trust F2, F7
transaction BEAM Common Stock Sale -$823K -9.86K -4.91% $83.49 191K Oct 6, 2021 By John M. Evans, III 2018 Irrevocable Trust F2, F8
transaction BEAM Common Stock Sale -$639K -7.57K -3.96% $84.45 183K Oct 6, 2021 By John M. Evans, III 2018 Irrevocable Trust F2, F9
transaction BEAM Common Stock Sale -$34.1K -400 -0.22% $85.24 183K Oct 6, 2021 By John M. Evans, III 2018 Irrevocable Trust F2, F10

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BEAM Stock Option (Right to Buy) Options Exercise $0 -27.7K -7.71% $0.00 332K Oct 6, 2021 Common Stock 27.7K $1.03 Direct F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $82.465 to $82.995, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $83.04 to $83.98, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $84.005 to $84.98, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $85.03 to $85.32, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $82.465 to $82.97, inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $83.08 to $83.98, inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $84.07 to $84.98, inclusive.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $85.07 to $85.31, inclusive.
F11 The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested.